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Immunization of mice with plasmids containing Trypanosoma cruzi genes induced specific antibodies, CD4
Th1 and CD8 Tc1 cells, and protective immunity against infection. In most cases, plasmids used for DNA
vaccination contained genes encoding antigens expressed by trypomastigotes, the nonreplicative forms of the
parasite. In this study, we explored the possibility of using genes expressed by amastigotes, the form of the
parasite which replicates inside host cells, for experimental DNA vaccination. For that purpose, we selected a
gene related to the amastigote surface protein 2 (ASP-2), an antigen recognized by antibodies and T cells from
infected mice and humans, for our study. Using primers specific for the asp-2 gene, four distinct groups of genes
were amplified from cDNA from amastigotes of the Y strain of T. cruzi. At the nucleotide level, they shared 82.3
to 89.9% identity with the previously described asp-2 gene. A gene named clone 9 presented the highest degree
of identity with the asp-2 gene and was selected for immunological studies. Polyclonal antisera raised against
the C terminus of the recombinant protein expressed by the clone 9 gene reacted with an antigen of approx-
imately 83 kDa expressed in amastigotes of T. cruzi. Immunization of BALB/c mice with eukaryotic expression
plasmids containing the clone 9 gene elicited specific antibodies and CD4 T-cell-dependent gamma interferon
secretion. Upon challenge with trypomastigotes, mice immunized with plasmids harboring the clone 9 gene
displayed reduced parasitemia and survived lethal infection. We concluded that amastigote cDNA is an
interesting source of antigens that can be used for immunological studies, as well as for vaccine development.
Trypanosoma cruzi is an obligate intracellular protozoan par-
asite and the etiologic agent of Chagas’ disease. Despite the
significant reduction in transmission observed in several coun-
tries in the last 20 years, Chagas’ disease is still a major health
problem for many Latin American countries, afflicting more
than 15 million individuals and causing thousands of deaths
every year. The poor prospect of treatment raises the possibil-
ity that immune interventions, such as immunization, could be
used as an additional weapon to improve disease prevention
and treatment efficacy.
Recently, independent groups established that immuniza-
tion with plasmids containing T. cruzi genes generated immune
responses mediated by antibodies, CD4 and CD8 T cells.
Mice vaccinated with DNA displayed remarkable protective
immunity, surviving otherwise lethal infection with T. cruzi (5,
9, 10, 28, 38, 45). Genes used for DNA vaccination against
experimental Chagas’ disease were mainly expressed by trypo-
mastigotes of T. cruzi. Genes expressed by amastigotes, the
form of the parasite that multiplies inside host cells, have only
very recently been subject to similar studies (10). Based on the
limited information on that subject, the present study was
designed to explore the possibility of using a gene expressed by
amastigotes for DNA vaccination against experimental Cha-
gas’ disease.
Toward that goal, to initiate our studies, we selected the
gene encoding amastigote surface protein 2 (ASP-2), a surface
antigen expressed by amastigotes of T. cruzi, that has been
described previously (19, 20, 26, 47). This protein was initially
described by Pan and McMahon-Pratt in 1989 (26) with the aid
of a stage- and species-specific monoclonal antibody (MAb)
raised against purified membrane components of T. cruzi
amastigotes. An 83-kDa antigen was purified with the aid of
the MAb, and its N-terminal amino acid sequence was deter-
mined. The observation that the purified antigen was specifi-
cally recognized by antibodies from individuals with Chagas’
disease residing in geographically distant regions of South
America was very important (26).
Based on the known N-terminal amino acid sequence, a
cDNA corresponding to an 83-kDa surface protein was cloned
by reverse transcription-PCR (RT-PCR) from RNA from
amastigotes. The protein encoded by this cDNA was named
ASP-2 (20). The predicted amino acid sequence encoded by
the asp-2 gene contains one aspartic acid box motif (ASP box;
SXDXGXTW) present in bacterial sialidases and the highly
conserved motif VTVXNVXLYNR characteristic of type
three module of fibronectin. On the basis of its predicted
primary structure, the asp-2 gene was assigned to subfamily II
of the sialidase/trans-sialidase gene superfamily of T. cruzi (6).
Using synthetic peptides based on the predicted amino acid
sequence encoded by the asp-2 gene, it was possible to dem-
onstrate that ASP-2 contains multiple major histocompatibility
complex (MHC) class I-restricted epitopes recognized by spe-
cific CD8 cytotoxic T lymphocytes (CTL) from mice and
humans infected with T. cruzi (19, 47). These CTL specific for
ASP-2 lysed target cells infected with T. cruzi, demonstrating
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that infected host cells process and present ASP-2 to CTL (19).
Together with the work by Pan and McMahon-Pratt (26), these
studies provided a strong immunological rationale for the se-
lection of ASP-2 to initiate our studies on DNA immunization
with genes expressed by amastigotes of T. cruzi.
In the present study, we characterized cDNA genes contain-
ing nucleotide sequences with high identity to the asp-2 gene
expressed by amastigotes of the Y strain of T. cruzi. A gene
named clone 9 shared the highest degree of identity with the
previously described asp-2 gene sequence and was selected for
immunological studies of experimental genetic vaccination.
BALB/c mice were immunized with eukaryotic expression plas-
mids harboring the clone 9 gene. In these mice, we studied the
presence of immune responses by looking at the presence of
specific antibodies and gamma interferon (IFN-)-secreting
spleen cells, as well as protective immunity against infection
with bloodstream trypomastigotes.
MATERIALS AND METHODS
Mice and parasites. Female 5- to 8-week-old BALB/c and C57BL/6 mice used
in this study were purchased from the University of Sa˜o Paulo.
Parasites of the Y strain of T. cruzi were used in this study (41). Epimastigotes
were maintained in liver infusion tryptose medium containing 10% (vol/vol) fetal
bovine serum (FBS) (Life Technologies) at 28°C. Intracellular amastigotes were
obtained from infected L6E6 cells (American Type Culture Collection, Rock-
ville, Md.) grown in RPMI medium (Life Technologies) containing 10% FBS at
37°C in an atmosphere containing 5% CO2. The intracellular forms were ob-
tained from infected cells by scraping the monolayer with the aid of a cell scraper
(Costar) in a buffer containing 27 mM K2HPO4, 8 mM Na2HPO4, and 26 mM
KH2PO4, pH 7.2. The cells were lysed with the aid of a Potter-Elvehjem homog-
enizer. The solution containing free parasites and cell debris was placed on top
of a Ficoll-Paque gradient (Pharmacia Biotech). After centrifugation at 800  g
for 20 min, the purified parasites were collected from the bottom of the tube.
Amastigotes were subsequently washed twice in plain RPMI medium.
Trypomastigotes were collected from the extracellular medium of infected
LLC-MK2 cells (kindly provided by S. Schenkman, Universidade Federal de Sa˜o
Paulo-Escola Paulista de Medicina [UNIFESP], Sa˜o Paulo, Brazil) 5 to 7 days
after infection, centrifuged at 2,000  g for 10 min, and recovered from the
supernatant 3 h later.
Bloodstream trypomastigotes were obtained from mice infected 7 days earlier.
Blood samples were collected from the axillary vein and transferred to a tube
containing heparin. After centrifugation, the parasites were collected with
plasma, centrifuged, and washed twice in phosphate-buffered saline (PBS). The
number of parasites was estimated and adjusted to a concentration of 75,000 per
ml. Each mouse was inoculated intraperitoneally with 0.2 ml (15,000 trypomas-
tigotes). Parasite development was monitored by counting the number of blood-
stream trypomastigotes in 5 l of fresh blood collected from the tail vein (17).
When there were more than 105 parasites per ml, the blood was diluted 10 times
in a solution containing 0.15 M NH4Cl, 1 mM KHCO3, and 0.1 mM EDTA, pH
7.0, to lyse red blood cells. The concentration of parasites was estimated with the
aid of a hematocytometer.
RNA purification and RT-PCR. Parasite RNA was purified from the different
developmental stages using TRIzol (Life Technologies) according to the manu-
facturer’s instructions. Subsequently, the RNA was treated with RNase-free
DNase I (Life Technologies) according to the protocol supplied by the manu-
facturer. The RNA was precipitated with ethanol, washed, and resuspended in
nuclease-free water. The cDNA reaction was performed with 2.5 g of total
RNA using the ThermoScript RT-PCR system (Life Technologies). The oli-
go(dT) primer supplied in the kit was used during the first strand reaction, and
the annealing temperature chosen was 60°C for 60 min. Further steps were
followed according to the manufacturer’s instructions. Control RT reactions
were performed in the absence of the enzyme.
Specific oligonucleotides were designed on the basis of the previously pub-
lished nucleotide sequence of the asp-2 gene (20). All oligonucleotides used in
this study were purchased from Life Technologies. The oligonucleotides and
their sequences were as follows: ASP-2F forward, 5-GGGGGTACCATGCTC
TCACGTGTTGCT-3; and ASP-GR reverse, 5-GGGTCTAGATCAGACCA
TTTTTAGTTCACC-3 (underlined nucleotides represent KpnI and XbaI sites,
respectively). For a control, we used a pair of primers specific for the sequence
of the T. cruzi -tubulin gene: TUBF forward (5-ACCGATGTTGCGGCGAT
GCTTGAC-3) and TUBR reverse (5-CCGCGCGCTGCACCTTGGCAA-3).
PCR was performed using the enzyme PLATINUM Pfx DNA polymerase
(Life Technologies) according to the protocol supplied by the manufacturer. The
annealing temperature used was 48°C, and the number of cycles was 35. PCR was
performed in a Perkin-Elmer 2400 GeneAmp PCR system. Amplification prod-
ucts were electrophoresed in 1% (wt/vol) agarose gels and visualized by ethidium
bromide staining and UV illumination. For DNA size markers, we used 
HindIII fragments or 100-bp DNA ladder (both purchased from Life Technol-
ogies).
Cloning and sequencing. A fragment of approximately 2.1 kb was excised from
agarose gels, and the DNA was purified with Geneclean II kit (BIO 101). The
purified product was cloned into the pMOSBlue vector (Amersham-Pharmacia),
and after restriction analysis using restriction enzymes EcoRI and XbaI (Life
Technologies), the clones containing inserts with the expected size were selected.
Twenty clones were then chosen and submitted to restriction analysis using
enzymes EcoRI, HindIII, and BamHI (Life Technologies).
Automatic sequencing of double-stranded DNA was performed using the
BigDye Terminator Cycle Sequencing kit (Perkin-Elmer) on an ABI PRISM 377
sequencer (Perkin-Elmer). Initially, U19 and T7 oligonucleotides (35) present in
the flanking regions of the pMOSBlue vector were used. Subsequently, to com-
plete the sequencing of each clone, new oligonucleotides were designed to cover
the entire sequence.
DNA and predicted amino acid sequences were analyzed using the DNA-
STAR package version 5.00 (DNASTAR, Inc.). Alignments were produced by
using the Clustal W program. Analysis for potential secretory signal peptide (SP)
was performed at the SignalP website (http//www.cbs.dtu.dk/services).
Pulsed-field gel electrophoresis, Northern blot analysis, and hybridization
conditions. DNA was prepared from T. cruzi epimastigotes as described previ-
ously (23). Agarose blocks of epimastigotes of T. cruzi were prepared, and
pulsed-field gel electrophoresis was performed at 18°C in 0.5 Tris-borate-
EDTA (TBE) (2), using contour-clamped homogeneous electric field apparatus
(Pharmacia Biotech). Chromosomes were fractionated on 1.2% (wt/vol) agarose
gels (chromosome-grade agarose; Bio-Rad). Electrophoresis was performed as
described previously (2). Gels were stained with ethidium bromide, photo-
graphed, and blotted under alkaline conditions to Hybond-N membranes (Am-
ersham). Hansenula wingei DNA fragments (Bio-Rad) (that had been prepared
using contour-clamped homogeneous electric field apparatus) ranging in size
from 1.05 to 3.13 Mb were used as molecular size markers.
Total RNA was resuspended in RNase-free water, equilibrated in a buffer
containing formamide, formaldehyde, and morpholinepropanesulfonic acid
(MOPS), heated for 30 min at 70°C, and fractionated in 1% agarose formalde-
hyde gels (35). RNA ladder ranging from 0.24 to 9.5 kb was used as size marker
(Life Technologies). Gels were photographed and transferred to membranes,
and the RNA was fixed and cross-linked to Hybond-N membranes by UV
irradiation.
Filters were prehybridized for 2 h at 42°C in a hybridization solution contain-
ing 50% (vol/vol) formamide (Sigma), 5 SSC (1 SSC is 0.15 M NaCl plus
0.015 M sodium citrate), 5Denhardt’s solution, 10 g of tRNA (Sigma) per ml,
and 100 g of salmon testes DNA (Sigma) per ml. Filters were hybridized
overnight at the same temperature with the indicated probes labeled with
[-32P]dCTP (Amersham) by using the Oligolabeling kit (Pharmacia Biotech)
according to the manufacturer’s instructions. The filters were washed in SSC
solutions (2 to 0.1) containing 0.1% (wt/vol) sodium dodecyl sulfate (SDS)
from 42 to 50°C and exposed to Hyperfilm (Amersham-Pharmacia).
Recombinant proteins based on the sequence of the clone 9 gene: plasmid
generation, Escherichia coli expression, and purification and production of spe-
cific antisera. For a bacterial expression vector, we used the pHIS plasmid kindly
provided by Peter Sheffield (University of Virginia) (39). Two plasmids were
generated based on the sequence of the clone 9 gene: pHIS-65kDa and pHIS-
25kDa. We selected these two plasmids for expression because attempts to
generate a recombinant protein with the entire clone 9 gene were not successful.
For plasmid pHIS-65kDa, the forward oligonucleotide (5-GGG AAT TCA
TGC CTC AAT GGG TC-3) was designed to anneal with nucleotides 232 to 246
of the clone 9 gene. For plasmid pHIS-25kDa, the forward oligonucleotide
(5-GGG GAT CCT GGT CTG GTT GGA TTC-3) was designed to anneal
with nucleotides 1474 to 1489 of the clone 9 gene (details in Table 1) (underlined
nucleotides represent EcoRI and BamHI sites, respectively). The reverse oligo-
nucleotide used in the PCR was ASP-GR described above. PCR was performed
using the enzyme PLATINUM Pfx DNA polymerase, and the annealing tem-
perature used was 48°C. The amplified PCR products were cloned into the
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pMOSBlue vector, removed by treatment with restriction enzymes EcoRI and
SalI, and ligated into the pHIS vector treated with the same enzymes.
Plasmids pHIS-65kDa and pHIS-25kDa were transformed into E. coli BL-21
expression host cells (Novagen, Madison, Wis.). Protein expression was obtained
by inoculation of 1 ml of a culture grown overnight in 100 ml of Luria broth
containing 100 g of ampicillin (Sigma) per ml. The culture was grown with
continuous shaking at 37°C to an optical density at 600 nm (OD600) of 0.6 and
then induced overnight at room temperature in the presence of 0.01 mM iso-
propyl-L-thio--D-galactoside (Life Technologies). Cells were harvested, centri-
fuged, and resuspended in 5 ml of a solution containing 1% (vol/vol) Triton
X-100 (Sigma), 4 mg of lysozyme (Sigma) per ml, and 1 mM phenylmethylsul-
fonyl fluoride (Life Technologies) dissolved in PBS. The suspension was then
transferred to cryogenic tubes and freeze-thawed three times in liquid nitrogen.
After centrifugation at 12,500  g for 20 min, the pellet was resuspended in 500
l of a denaturing solution containing 8 M urea, 100 mM Tris-HCl (pH 9.0), 20
mM dithiothreitol (Life Technologies), and 3 mM EDTA (Sigma). After cen-
trifugation at 12,500  g for 10 min, SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) sample buffer (35) containing 5% (vol/vol) 2-mercaptoethanol was
added to 200 l of the supernatant, and the sample was boiled for 3 min. These
samples were subjected to electrophoresis on gels consisting of 10 or 12.5%
(wt/vol) polyacrylamide and 0.1% (wt/vol) SDS. Gels were stained with a solution
of 250 mM KCl, and the band corresponding to the recombinant protein was
excised using a razor blade. The gel bands were cut in small pieces and eluted
overnight in distilled water at room temperature under constant agitation. The
volume was reduced with the aid of a Hetovac (Heto, Scandinavia). The purity
of recombinant protein was determined by SDS-PAGE. For molecular size
standards, SDS-molecular weight marker kit (Sigma) or Benchmarker Prestained
Protein Ladder (Life Technologies) was used.
Before recombinant proteins were used in cell cultures, SDS was removed by
dialysis against distilled water overnight at 4°C. Water was changed four times.
Protein concentration was determined by gel electrophoresis using known con-
centrations of bovine serum albumin (BSA) (Sigma) as the standard.
C57BL/6 mice were immunized with 100 g of the purified recombinant
protein (His-25kDa) in complete Freund’s adjuvant (CFA) in the hind foot. Two
weeks later, mice were bled, and their sera were used for immunological assays.
Eukaryotic expression vectors: plasmid generation, purification, and immu-
nization. Commercially available plasmid pcDNA3 (Invitrogen, San Diego, Cal-
if.) was used as the mammalian expression vector. Plasmid pclone9 was gener-
ated by inserting the clone 9 gene into the EcoRI and XbaI sites of plasmid
pcDNA3 (details in Table 1). Plasmid pSPclone9 was generated by inserting the
nucleotide sequence encoding the signal peptide of hemagglutinin protein from
the influenza virus in frame with the 5 nucleotide sequence of the clone 9 gene
into the pclone9 plasmid. The nucleotides encoding the hemagglutinin protein
SP (15) were obtained from a plasmid kindly provided by Sang Won Han
(UNIFESP, Sa˜o Paulo, Brazil) and inserted using the HindIII and BamHI sites
of the pcDNA3 vector containing the clone 9 gene. Plasmid pIgSPclone9 was
obtained by inserting the nucleotide sequence encoding the mouse immunoglob-
ulin 	 chain SP (IgSP) in frame with the 5 nucleotide sequence of the clone 9
gene. The nucleotide sequence encoding IgSP was generated from annealing six
different oligonucleotides synthesized on the basis of the sequence described in
reference 14. This product was subcloned into the KpnI site from pcDNA3
plasmid. The clone 9 gene was subsequently cloned into KpnI and XbaI sites of
pcDNA3. The presence of the nucleotides encoding the hemagglutinin protein
SP or IgSP was confirmed by direct sequencing of plasmids pSPclone9 and
pIgSPclone9 using the T7 oligonucleotide present in the 5-flanking region of the
pcDNA3 vector. Plasmid p154/13 containing the catalytic domain of T. cruzi
trans-sialidase used as a positive control in a few experiments was generated as
described previously (5).
Plasmids were produced in E. coli DH5 and purified on cesium chloride
density gradients according to standard protocols (35). DNA concentration was
estimated to be 260 nM and confirmed by agarose gels stained with ethidium
bromide. Each plasmid DNA was diluted in sterile PBS to a concentration of 1
mg/ml.
BALB/c mice were immunized according to a protocol described earlier (5).
Both tibialis anterioris muscles were injected with 3.5 g of cardiotoxin (Sigma).
Five days later, 50 g of plasmid DNA was injected intramuscularly (i.m.) at the
same sites as for cardiotoxin injection (a total of 100 g of plasmid DNA per
mouse). The subsequent doses consisted of the same amount of plasmid DNA
injected 3, 5, and 7 weeks after the first dose.
Ten days to five weeks after the last dose, mice were used for immunological
studies or challenged with bloodstream trypomastigotes.
Immunoblotting. Parasites of the different stages of T. cruzi were obtained as
described above. After the samples were washed in PBS twice, the parasite
concentration was estimated by counting them with a hematocytometer and their
concentration was adjusted to 109 parasites per ml. Parasite extracts were ob-
tained by treating the parasites with a solution of PBS containing a final con-
centration of 1% (vol/vol) NP-40 and proteolytic enzyme inhibitors (1 mM
phenylmethylsulfonyl fluoride and 1 mM iodoacetamide [Sigma]). After centrif-
ugation for 5 min at 12,500  g, the supernatants were collected, mixed with
SDS-PAGE sample buffer containing 2-mercaptoethanol and boiled for 3 min.
The amount of liquid corresponding to 107 parasites was loaded onto SDS-
polyacrylamide gels. After electrophoresis, the samples were transferred to ni-
trocellulose membranes (Millipore) for 1 h at 100 V and 4°C. The membranes
were treated with PBS containing 5% (wt/vol) dry nonfat milk and 2% (wt/vol)
BSA for at least 2 h and incubated with a pool of sera from mice immunized with
the recombinant His-25kDa protein (diluted 1:750). After extensive washes with
PBS containing 0.05% (vol/vol) Tween 20 (PBS-Tween), bound antibodies were
detected by incubating the immunoblot membranes with peroxidase-conjugated
goat anti-mouse immunoglobulin G (IgG) (Life Technologies) (diluted 1:2,000)
and visualizing the chemoluminescence reaction with enhanced chemilumines-
cent reagent (Amersham-Pharmacia) and exposure to Hyperfilm.
ELISA and indirect immunofluorescence assay (IIA). Antibodies were de-
tected by enzyme-linked immunosorbent assay (ELISA) using microtiter poly-
styrene plates (high binding; Costar) coated with the recombinant protein His-
65kDa. Each well was incubated overnight at room temperature with 0.125 g of
the recombinant protein dissolved in 0.05 M NaHCO3/Na2CO3 buffer, pH 9.6, in
a final volume of 50 l. Unbound antigen was removed by washing the plates
three times with PBS-Tween. Wells were blocked with PBS containing 5%
(wt/vol) dry nonfat milk and 2% (wt/vol) BSA. After 2 h, 50-l serum samples
(diluted 800 times) from immunized and control mice were incubated for 60 min
at room temperature. After five washes with PBS-Tween, wells were incubated
for 60 min at room temperature with anti-mouse IgG conjugated to peroxidase
(KPL) diluted 1:4,000. Bound immunocomplexes were detected with o-phenyl-
enediamine (Sigma). Plates were read at OD492 on an ELISA reader (Lab-
systems Multiskan MS).
For IIA, parasites or infected cells were fixed for 30 min in PBS containing the
nonpermeabilizing reagent paraformaldehyde (Merck) (3.5% [vol/vol]). After
fixation, parasites were washed twice with PBS, and the solution was adjusted to
a concentration of 107 parasites per ml. Ten-microliter portions of the parasite
suspension were layered onto round, coated coverslips and allowed to stand








of clone 9 gene
Additional sequence in the N-terminal regiona No. of aa inpolypeptide
pHIS-25kDa pHIS 1474–2085 492–694 MSYYHHHHHHDYDIPTTENLYFQGAMDPM 231
pHIS-65kDa pHIS 232–2085 78–694 MSYYHHHHHHDYDIPTTENLYFQGAMDPM 645
pclone9 pcDNA3 1–2085 1–694 None 694
pSPclone9 pcDNA3 1–2085 1–694 MKTIIALSYIFCLVFADYKDDDDAMDPLVTAA
SVLEFCRYPSHWRPILE
742
pIgSPclone9 pcDNA3 1–2085 1–694 MGMQVQIQSLFLLLLWVPGSRGGT 718
pIgSP pcDNA3 None None MGMQVQIQSLFLLLLWVPGSRG 22
pcDNA3 pcDNA3 None None None 0
a The sequences shown in boldface type are the hexahistidine tag (HHHHHH), influenza virus hemagglutinin (SP MKTIIALSYIFCLVFA), and mouse Ig 	 chain
SP (MQVQIQSLFLLLLWVPGSRG).
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overnight at room temperature. Coverslips were stored at 
20°C until use.
Infected cells were permeabilized by treatment with PBS containing 0.2% (vol/
vol) Triton X-100 for 15 min at room temperature. Blocking was performed for
30 min at room temperature in PBS containing 3% (wt/vol) BSA. Sera from mice
immunized with plasmid pclone9 were diluted to 1:25 in PBS-BSA and allowed
to react for 30 min at room temperature. After three washes in PBS-Tween,
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Sigma) di-
luted 1:25 was added for an additional 60 min. Coverslips were covered with 50%
(vol/vol) glycerol carbonate–0.5 M bicarbonate buffer and observed using an
Optishot-2 fluorescence microscope (Nikon). IIA images were acquired with a
Zeiss Axiovert microscope attached to a Bio-Rad 1024UV confocal microscope
using a 100 1.4 (aperture) differential interference contrast PlanApo objective.
Cell cultures and detection of IFN- and NO. Cells were cultured in RPMI
medium (Life Technologies) supplemented with 10 mM HEPES, 2 mM L-
glutamine, 5  10
5 M 2-mercaptoethanol, 1 mM sodium pyruvate, 1% (vol/vol)
nonessential amino acid solution, 1% (vol/vol) MEM vitamin solution (all pur-
chased from Life Technologies), 100 U of penicillin and streptomycin (Sigma)
per ml, and 2% (vol/vol) normal human serum. The cultures were maintained at
37°C in an atmosphere containing 5% CO2.
Cells were obtained from the spleens of three BALB/c mice immunized with
plasmid pclone9, pSPclone9, pIgSPclone9, or pcDNA3. Red blood cells were
lysed in a solution of 0.15 M NH4Cl, 1 mM KHCO3, and 0.1 mM EDTA, pH 7.0.
These cells were washed three times in plain RPMI medium and resuspended in
complete medium to a concentration of 20  106 viable cells per ml. The assay
was performed in 96-well flat-bottom plates (Costar); 0.2 ml of cell suspension
was pipetted into each well, and the antigen was added at the desired concen-
tration. Recombinant His-65kDa protein was added at final concentrations rang-
ing from 10 to 0.1 g/ml. Recombinant trans-sialidase (TS) containing the cat-
alytic domain of T. cruzi TS used as a positive control in a few experiments was
generated as described previously (5, 9, 30). Rat IgG and purified anti-CD4
(GK1.5) and anti-CD8 MAbs (2.43) were added to a final concentration of 10
g/ml. We collected supernatants for cytokine determination after 5 days of
culture. Each determination was done in triplicate; results are reported as means
 standard deviations (SDs).
The concentration of IFN- or interleukin-4 (IL-4) was estimated by capture
ELISA using commercially available antibodies and recombinant cytokine
(Pharmingen, San Diego, Calif.) exactly as described earlier (30). The concen-
tration of cytokine in each sample was determined from standard curves exe-
cuted in parallel with known concentrations of recombinant IFN- or IL-4. The
detection limit of the assays was 0.2 ng/ml.
Nitrite production by cultured cells was assessed by incubation of 50 l of each
supernatant with 50 l of Griess solution (1% [wt/vol] sulfanilamide, 0.1%
[wt/vol] naphthylene diamine dihydrochloride, 2% [vol/vol] H3PO4; all pur-
chased from Sigma). The absorbance was measured at OD540 on an ELISA
reader. Known concentrations of sodium nitrite diluted in culture medium were
used as standards.
ELISPOT assay for the detection of peptide-specific IFN--producing cells.
The enzyme-linked immunospot (ELISPOT) assay was performed essentially as
described earlier (25, 29). Briefly, the plates were prepared by coating the wells
of 96-well Multiscreen HA nitrocellulose plates (Millipore) with a solution of
sterile PBS containing 10 g of the anti-mouse IFN- MAb R4-6A2 (Pharmin-
gen) per ml (60 l of the PBS-MAb solution was used to coat each well). After
overnight incubation at room temperature, the MAb solution was removed by
sterile aspiration and the plates were washed three times with plain RPMI
medium under sterile conditions. Plates were blocked by incubating wells with
100 l of RPMI medium containing 10% (vol/vol) FBS for at least 2 h at 37°C.
Responder cells were obtained from the spleens of three BALB/c mice im-
munized four times with plasmid pclone9, pIgSPclone9, or pcDNA3. For a
positive control, we used spleen cells from three BALB/c mice immunized with
plasmid p154/13. Responder cells were washed three times in plain RPMI me-
dium and resuspended in complete RPMI medium to a concentration of 5  106
viable cells per ml. Complete RPMI medium was produced as described above
except that it contained 10% (vol/vol) FBS (HyClone, Logan, Utah), and we
added recombinant human IL-2 (kindly provided by Hoffman-LaRoche) (30
U/ml) to the medium.
Antigen-presenting cells were prepared by irradiating A20J cells (kindly pro-
vided by Moriya Tsuji, New York University School of Medicine) for 45 min.
These cells express MHC class I and II molecules that improve peptide presen-
tation to specific T cells. Cells were then washed three times in plain RPMI
medium. Their viability was determined by trypan blue dye exclusion, and their
concentration was adjusted to 106 cells/ml in complete RPMI medium. Some
cells were incubated with the indicated synthetic peptide at a final concentration
of 4 M for 30 min at 37°C.
One hundred microliters of a suspension containing responders or antigen-
presenting cells was pipetted into each well. The plates were incubated (without
shaking) for 24 h at 37°C in an atmosphere containing 5% CO2.
After incubation, the majority of the cultured cells were flicked off the plates.
To remove residual cells, plates were washed three times with PBS and three
times with PBS-Tween. Each well received 75 l of biotinylated anti-mouse
IFN- MAb XMG1.2 (Pharmingen) diluted in PBS-Tween to a final concentra-
tion of 2 g/ml. Plates were incubated overnight at 4°C. Unbound antibodies
were removed by washing the plates at least six times with PBS-Tween. Peroxi-
dase-labeled streptavidin (KPL) was added at a 1:800 dilution in PBS-Tween in
a final volume of 100 l/well. Plates were incubated for 1 to 2 h at room
temperature and then washed three to five times with PBS-Tween and three
times with PBS.
The reactions on the plates were developed by adding peroxidase substrate (50
mM Tris-HCl [pH 7.5] containing 3,3-diaminobenzidine tetrahydrochloride [1
mg/ml] and 30% hydrogen peroxide solution [1 l/ml] [both from Sigma]) (100
l/well). After incubation at room temperature for 15 min, the reaction was
stopped by discarding the substrate solution and rinsing the plates under running
tap water. Plates were dried at room temperature, and spots were counted with
the aid of a stereomicroscope (Nikon).
Synthetic peptides. Synthetic peptides based on the predicted amino acid
sequence of the clone 9 gene were purchased from New England Peptides
(Fitchburg, Mass.). As estimated by high-pressure liquid chromatography anal-
ysis, the purity of the synthetic peptides varied from 78 to 99%. Synthetic peptide
TS359-367 (IYNVGQVSI) was purchased from Neosystem (Strasbourg, France).
As estimated by high-pressure liquid chromatography analysis, TS359-367 was
more than 90% pure.
Statistical analysis. The Student t test was used to compare the possible
differences in the mean values of IFN- and nitrite concentrations. The peak
parasite loads observed in the different mouse groups were compared by one-way
analysis of variance (ANOVA) and Tukey’s honestly significant difference
(HSD) tests. The Mann-Whitney test was used to compare the OD492s obtained
by ELISA using sera from mice immunized with the different plasmids. Log-rank
test was used to compare mouse survival times after challenge with T. cruzi. The
differences were considered significant when the P value was 0.05.
Nucleotide sequence accession numbers. The nucleotide sequences reported
in this paper have been deposited in GenBank with accession numbers
AY186572 (clone 9), AY186574 (clone 13), AY186575 (clone 105), and
AY186576 (clone 117).
RESULTS
Identification and characterization of genes related to asp-2
present in the cDNA of amastigotes of the Y strain of T. cruzi.
In an attempt to characterize genes expressed by the Y strain
of T. cruzi related to the previously described asp-2 gene,
RT-PCR was performed using an oligo(dT) primer, a pair of
primers based on the published sequence of asp-2, and RNA
extracted from the different developmental stages of the par-
asite. A single band of 2.1 kb was obtained by RT-PCR using
RNA from amastigotes or epimastigotes (Fig. 1A). PCR prod-
ucts were not observed in the absence of reverse transcriptase.
In contrast, in several independent experiments, specific
PCR products were not detected when RT-PCR was per-
formed using trypomastigote RNA. This absence cannot be
attributed to the trypomastigote RNA itself, because specific
PCR products could be readily obtained in the presence of
primers specific for the -tubulin gene of T. cruzi (Fig. 1B).
DNA products obtained from PCR using cDNA from amas-
tigotes were cloned into the pMOSBlue vector. Twenty clones
were subjected to restriction analysis, and four different restric-
tion patterns (named 1 through 4) were observed. Clones be-
longing to restriction pattern 1 or 2 were more common in the
cDNA representing 9 or 5 of the 20 clones studied, respec-
tively. Restriction patterns 3 and 4 were less represented in the
amastigote cDNA (each corresponding to 3 of the 20 clones).
Similar proportions were observed when we studied clones
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isolated from different RT-PCR mixtures. The observation
made when we performed PCR using an oligonucleotide rep-
resenting the splice leader sequence of T. cruzi as the forward
primer was also important. Using this oligonucleotide as a
primer, restriction pattern 1 or 2 represented 12 or 6 of 18
clones studied, respectively. Clones representing restriction
pattern 3 or 4 were not observed in this case (data not shown).
We consider this result important, because the splice leader
sequence is present only in mature mRNA of T. cruzi.
DNA sequences were obtained from two clones representing
each restriction pattern. Comparison of the DNA sequences of
the two clones representing each pattern showed minor but
significant differences, indicating that they were distinct genes
(data not shown). We selected clones 9, 13, 117, and 105 to
represent restriction patterns 1, 2, 3, and 4, respectively. The
clone 9 gene shared the highest degree of identity with the
asp-2 gene (89.9 or 82.7% identity at the nucleotide or pre-
dicted amino acid sequence levels, respectively). The other
genes revealed decreasing degrees of identity with the asp-2
gene sequence.
At the nucleotide level, clone 117 (pattern 3) and clone 105
(pattern 4) presented a high degree of identity when compared
to each other (98.4%). The clone 117 and clone 105 genes had
stop codons at nucleotides 309 and 285, respectively. Despite
the identity with asp-2, all genes isolated from amastigote
cDNA with restriction pattern 3 or 4 had stop codons in their
5 region. These genes most likely represent pseudogenes
which are transcribed but not translated in T. cruzi (1). Figure
2 shows a Clustal W multiple-sequence alignment of the pre-
dicted amino acid sequences of clones 9, 13, 117, 105, and the
previously described asp-2 gene. The predicted amino acid
sequences of clone 9 or clone 13 contain a sequence encoding
a highly probable SP sequence at the N terminus that contains
a strongly hydrophobic, noncharged core represented by amino
acids (aa) 39 to 66. The predicted cleavage site of SP is be-
tween aa 66 to 67 (Fig. 2).
The predicted amino acid sequence of the clone 13 or clone
9 gene contains, respectively, one or two ASP box motifs
(SXDXGXTW) present in bacterial sialidases. Both genes
contain the sequence encoding the highly conserved motif
VTVXNVXLYNR characteristic of type three module of fi-
bronectin. These sequences are common to members of the
sialidases/trans-sialidase gene superfamily of T. cruzi (6).
Because the clone 9 gene shared the highest identity with the
asp-2 gene sequence, it was selected for subsequent studies.
The genomic distribution of the clone 9 gene was determined
by chromosome mapping, and this gene hybridized with many
chromosomal bands of the Y strain genome (Fig. 3A, lane 2).
Similar results were observed when we used the clone 13 gene
(data not shown). In contrast, the parasite -tubulin gene used
as a control hybridized only with two bands of the Y strain
genome (Fig. 3A, lane 3). This result indicates that the clone 9
and clone 13 genes belong to a relatively large family of genes
distributed in different chromosomes of the parasite.
By Northern blotting, the clone 9 gene hybridized with two
RNA populations of different sizes present in the different
developmental stages of the parasite. The shorter RNA pop-
ulation was detected in RNA isolated from amastigotes or
epimastigotes. The longer RNA population was detected in
trypomastigotes or epimastigotes (Fig. 3B). Identical results
were obtained when the clone 13 gene was hybridized with
RNA purified from the different developmental stages of the
parasite (data not shown).
Antisera raised against the C terminus of the recombinant
protein encoded by the clone 9 gene recognizes an 83-kDa
protein in amastigotes of T. cruzi. To verify whether the clone
9 gene did in fact encode a protein with characteristics similar
to those of ASP-2, a pHIS protein expression construct was
designed on the basis of the clone 9 sequence for the produc-
tion of a fusion protein, development of specific polyclonal
antisera, and immunoblot analysis. The pHIS construct His-
25kDa (Table 1) represented the C terminus of the recombi-
nant protein encoded by the clone 9 gene. We selected this
region of the protein, because its predicted amino acid se-
quence shared a high degree of identity (180 of 203 aa) with
the same region of ASP-2 (Fig. 2).
Sera from mice immunized with the fusion protein were
employed to develop immunoblots containing extracts of try-
pomastigotes, amastigotes, and epimastigotes, as well as the
recombinant protein. As shown in Fig. 4, the recombinant
protein His-25kDa (lane 5) and a single band of 83 kDa
present in extracts of amastigotes of T. cruzi (lane 7) were
recognized. Two smaller proteins of 67 and 47 kDa were
recognized in extracts of trypomastigotes and epimastigotes,
respectively (lanes 6 and 8). Antibody recognition was specific,
because sera from mice immunized with CFA alone failed to
react with any protein (lanes 1 to 4).
Presence of specific antibodies in the sera of mice immu-
nized with eukaryotic expression vectors containing the clone 9
gene. In order to study the immune response induced by DNA
immunization with different eukaryotic expression plasmids,
we used three different plasmids containing the clone 9 gene.
These three plasmids differ in the presence in the 5 region of
the clone 9 gene of a DNA sequence encoding a secretory
FIG. 1. RT-PCR using RNA purified from different developmental
stages of the Y strain of T. cruzi and oligonucleotide primers based on
the previously described asp-2 gene sequence. RT-PCR was performed
using oligo(dT) primer and total RNA purified from trypomastigotes
(T), amastigotes (A), and epimastigotes (E) of T. cruzi (Y strain) in the
presence () or absence (
) of the reverse transcriptase (RT) enzyme.
PCR was performed using a pair of primers based on the previously
described sequence of the asp-2 gene (A) or T. cruzi -tubulin gene (B).
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FIG. 2. Clustal W multiple-sequence alignment of the predicted amino acid sequences of clone 9, 13, 117, and 105 genes isolated from
amastigote cDNA of the Y strain of T. cruzi and the previously described asp-2 gene. The predicted amino acid sequences of clone 9 (pattern 1),
clone 13 (pattern 2), clone 117 (pattern 3), and clone 105 (pattern 4) are shown. A black background indicates 100% identity in the predicted amino
acid sequences among all clones analyzed. A gray background indicates 100% identity in the predicted amino acid sequences among the asp-2, clone
9, and clone 13 genes. Red letters indicate 100% identity in the predicted amino acid sequences for the clone 9 and asp-2 genes. Dashes represent
gaps introduced for optimal alignment.
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SP. While pclone9 contained only the clone 9 gene, plasmid
pSPclone9 or pIgSPclone9 also contained DNA sequences en-
coding the secretory SP of the influenza virus hemagglutinin or
mouse Ig 	 light chain, respectively (Table 1).
BALB/c mice were immunized i.m. with plasmid pclone9,
pSPclone9, or pIgSPclone9. Control mice were immunized
with pcDNA3 or pIgSP. The presence of specific antibodies
was determined by ELISA using the recombinant protein His-
65kDa as an antigen (Table 1). Specific antibodies were de-
tected in most of the animals immunized with each of the three
plasmids containing the clone 9 gene (Fig. 5).
By IIA, it was possible to determine that intra- and extra-
cellular amastigotes, but not extracellular trypomastigotes, of
T. cruzi were specifically recognized by antibodies from mice
immunized with plasmid pclone9 (Fig. 6B and D). IIA results
were negative when we used sera from mice immunized with
control plasmid pcDNA3 (data not shown).
Cellular immune responses of mice immunized with eukary-
otic expression plasmids containing the clone 9 gene. Next, we
assessed whether immunization with eukaryotic expression
plasmids containing the clone 9 gene elicited a cell-mediated
immune response, as estimated in vitro by antigen-specific IFN-
or IL-4 secretion. Upon in vitro stimulation with the recombi-
nant protein His-65kDa but not TS, spleen cells from mice
immunized with plasmid pclone9, pSPclone9, or pIgSPclone9
secreted IFN-. This response was dependent on in vivo prim-
ing, because spleen cells from mice injected with control plas-
mid pcDNA3 failed to secrete IFN- upon stimulation with the
recombinant protein (Table 2). These supernatants were also
tested for the presence of the type 2 cytokine IL-4. On re-
peated occasions, we were unable to detect it (data not shown).
Secretion of IFN- was dependent on the activation of
CD4 T cells. When compared to culture containing rat IgG,
the presence of an anti-CD4 MAb significantly inhibited the
antigen-specific IFN- production by spleen cells of mice im-
munized with plasmid pclone9, pSPclone9, or pIgSPclone9
(P  0.01 in all cases) (Table 2). In contrast, the addition of an
anti-CD8 MAb to the cultures did not cause a significant re-
duction in the IFN- secretion by these spleen cells (P  0.05
in all cases) (Table 2). The addition of both MAbs did not
further increase the inhibition observed in the presence of an
anti-CD4 MAb (Table 2).
In addition to IFN- production, we measured the presence
of NO in the supernatants of spleen cell cultures. Upon in vitro
stimulation with the recombinant protein His-65kDa, a signif-
icant increase in NO concentration was observed in the super-
natants of spleen cells from mice immunized with plasmids
containing the clone 9 gene (P  0.05) (Table 3). In contrast,
NO concentrations in the supernatants of spleen cells from
mice immunized with the control plasmid pcDNA3 cultured in
the presence or absence of the recombinant protein His-65kDa
were not statistically different (P  0.05) (Table 3).
The increase in the NO concentration in the supernatant of
spleen cells stimulated by the recombinant protein His-65kDa
was dependent on the activation of CD4 T cells. As found for
IFN- secretion, the addition of an anti-CD4 MAb significantly
reduced the NO accumulation in the supernatant of cultures
containing spleen cells from mice immunized with plasmid
pclone9 (Table 4).
In order to determine whether we could detect specific
FIG. 3. Chromosome location and Northern blot analysis using the
clone 9 gene as a probe. (A) Chromosome mapping of the clone 9 gene
was performed by pulsed-field gel electrophoresis using DNA from
epimastigotes. Chromosomes were stained with ethidium bromide
(lane 1) and blotted onto nylon membranes. Membranes were hybrid-
ized with the radioactively labeled clone 9 gene (lane 2) or with T. cruzi
-tubulin gene (lane 3). (B) Northern blot analysis was performed
using total RNA purified from trypomastigotes (T), amastigotes (A),
or epimastigotes (E) of T. cruzi (Y strain).
FIG. 4. Immunoblot using sera collected from mice immunized
with the purified recombinant protein His-25kDa. Purified recombi-
nant protein His-25kDa (0.3 g) or parasite extracts (equivalent to 107
parasites) were added to each lane of a SDS-polyacrylamide gel (re-
ducing conditions). Immunoblot strips contained the recombinant pro-
tein His-25kDa (lanes 1 and 5) or extracts of trypomastigotes (lanes 2
and 6), amastigotes (lanes 3 and 7), or epimastigotes (lanes 4 and 8).
These strips were incubated with a pool of sera from mice immunized
with CFA alone (lanes 1 to 4) or CFA plus purified recombinant
protein His-25kDa (lanes 5 to 8).
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CD8 T cells in the spleens of mice immunized with plasmid
pclone9 or pIgSPclone9, we synthesized 14 peptides based on
the predicted amino acid sequence of the clone 9 gene. Pep-
tides were selected by the presence of putative sites for binding
to the MHC class I H-2Kd or H-2Ld gene product of BALB/c
mice (4, 7). Peptides with putative sites for binding to H-2Dd
were not present in the predicted amino acid sequence of the
clone 9 gene (3).
Spleen cells from mice immunized with DNA were tested by
the ELISPOT assay for their ability to secrete IFN- upon in
vitro stimulation with target A20J cells coated with each of
these peptides. This assay was selected because it is very sen-
sitive and specific (25, 29). In repeated experiments, we could
not detect the presence of peptide-specific IFN--secreting
cells in the spleens of mice immunized with plasmid pclone9 or
pIgSPclone9 (Table 5). This failure could not be attributed to
the ELISPOT assay itself or to the responder cells, because
IFN- secretion could be detected when we used the recom-
binant protein His-65kDa as the antigen (Table 5). Also, we
detected the presence of IFN--secreting cells in the spleens of
mice immunized with plasmid p154/13 which contains the gene
encoding the catalytic domain of T. cruzi TS. These cells were
specific for the TS359-367 peptide (IYNVGQVSI) described as
a CD8 T-cell epitope in our earlier study (30).
Protective immunity in mice immunized with plasmids con-
taining the clone 9 gene. In order to determine whether DNA
immunization could induce protective immunity against T.
cruzi infection, BALB/c mice immunized with plasmid pclone9,
pSPclone9, or pcDNA3 were challenged with bloodstream try-
pomastigotes. In mice immunized with plasmid pclone9 or
pSPclone9, we observed a significant reduction in the peak
parasite level compared to those in animals immunized with
pcDNA3 plasmid (P  0.0001 by one-way ANOVA) (Fig. 7A).
Most importantly, none of the mice immunized with plasmid
pclone9 or pSPclone9 died (Fig. 7B). While 100% of the ani-
mals immunized with plasmid pclone9 or pSPclone9 survived
the infection, 90% of mice injected with plasmid pcDNA3
died. This experiment was reproduced with identical results. In
both experiments, a total of 36 BALB/c mice were immunized
with plasmid pclone9 or pSPclone9. All animals survived the
infection. In contrast, 16 of the 17 mice immunized with
pcDNA3 died (P  0.0001 by log-rank test).
DISCUSSION
The aim of our study was to explore the possibility of using
genes expressed by amastigotes, the intracellular replicating
forms of T. cruzi, for experimental DNA vaccination. For that
purpose, we selected for our study the gene encoding the
ASP-2 protein, an antigen recognized by antibodies, as well as
potentially protective immune T cells from mice and humans
infected with T. cruzi (19, 26, 47).
In a detailed characterization of the asp-2 cDNA expressed
by amastigotes of T. cruzi (Y strain), we isolated cDNA genes
displaying four distinct restriction patterns. Each restriction
pattern may include two or more distinct genes. Sequence
analysis of these genes revealed 82.3 to 89.9% identity at the
nucleotide level with the previously described asp-2 gene iso-
lated from the cDNA of the Brazil strain of T. cruzi. On the
basis of their high degree of identity with the asp-2 gene, they
can be assigned as new members of subfamily II of the siali-
dase/trans-sialidase gene superfamily of T. cruzi. Southern blot
hybridization using clone 9 and clone 13 genes confirmed that
they belong to a family of genes distributed in multiple chro-
mosomes of the Y strain genome. The isolation of these cDNA
clones defined a new group of genes similar to asp-2 expressed
in the replicating forms of T. cruzi.
Members of subfamily II have been shown to be expressed in
both trypomastigotes and amastigotes of T. cruzi (6, 8, 16, 20,
27, 33, 34, 36). RT-PCR analyses using specific primers showed
FIG. 5. Antibody immune response of mice immunized with eu-
karyotic expression plasmids containing the clone 9 gene. BALB/c mice
were immunized with plasmids containing the clone 9 gene (pclone9,
pSPclone9, and pIgSPclone9) or control (empty) plasmids (pcDNA3
or pIgSP). Two weeks after the last immunization, blood samples were
collected, and the sera were assayed by ELISA for the presence of
antibodies to the recombinant protein His-65kDa. Results are pre-
sented as the OD492s of each individual serum sample diluted 800
times. The OD492 values of the different groups were compared by the
Mann-Whitney test. The P values for the OD492 values of the different
groups were as follows: P  0.001 for pclone9 versus pcDNA3, P 
0.001 for pSPclone9 versus pcDNA3, P  0.0466 for pclone9 versus
pSPclone9, and P  0.001 for pIgSPclone9 versus pIgSP.
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that the presence of genes related to asp-2 in the Y strain of T.
cruzi is restricted to the cDNA of amastigotes and epimastig-
otes (Fig. 1A). In contrast, Northern blot analysis reproducibly
revealed the presence of mRNA that hybridizes with clone 9
and clone 13 genes in the different developmental stages of the
parasite, including trypomastigotes. Unlike amastigotes, trypo-
mastigotes had a longer form of RNA not seen in the intra-
cellular stages (Fig. 3B). These contrasting results can be ex-
plained by the fact that PCR was performed with cDNA
generated with an oligo(dT) primer. It is possible that North-
ern blot analysis detected trypomastigote mRNA which does
not contain a poly(A) tail. In agreement with this possibility is
the fact that specific amplification products were obtained
when PCR was performed with trypomastigote cDNA gener-
ated by RT in the presence of the reverse 3 oligonucleotide
ASP-GR (data not shown).
Alternatively, it is possible that clone 9 and clone 13 genes
hybridized with mRNA from other members of subfamily II
expressed in trypomastigotes of T. cruzi. Indeed, comparison of
clone 9 nucleotide sequence with other genes available in Gen-
Bank revealed 62 to 63.6% identities with several genes
present in trypomastigote cDNA (GenBank accession num-
bers L31947/Z32744, M58466, U02613, U02615, and L13844
[8, 33, 34]).
The fact that we found four distinct groups of genes in PCR
products of cDNA from amastigotes raised the question of
FIG. 6. IIA recognition of amastigotes, but not of trypomastigotes, of T. cruzi by immune sera from mice immunized with a plasmid containing
the clone 9 gene. Intracellular amastigotes (A and B) or mixtures of extracellular amastigotes and trypomastigotes from cultures (C and D) were
analyzed by IIA. Parasites were incubated with a pool of sera derived from mice immunized with plasmid pclone9 and imaged under Nomarski
differential interference contrast (A and C) or fluorescence (B and D) microscopy. Bars, 10 and 50 m.
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which one actually encodes the Y strain ASP-2. Clones repre-
senting restriction pattern 1, for example, the clone 9 gene,
represented the majority of clones obtained by RT-PCR using
RNA from amastigotes. Also, at the level of predicted amino
acid sequences, the clone 9 gene exhibited the highest identity
with the asp-2 gene (82.7%). The second group of genes most
commonly isolated from amastigote cDNA was represented by
the clone 13 gene. At the level of predicted amino acid se-
quence, this gene displayed lower degrees of identity with the
asp-2 and clone 9 genes (72 and 71.1%, respectively).
The above observations led us to select the clone 9 gene as
the most likely candidate for the gene encoding ASP-2 of T.
cruzi (Y strain). In support of this hypothesis, we found that
antibodies prepared against a recombinant protein based on
the C terminus of the protein encoded by the clone 9 gene
recognized a band of 83 kDa in amastigote extracts on an
immunoblot. This result lends further support that the clone 9
gene does indeed encode at least part of the ASP-2 antigen
expressed by amastigotes of the Y strain of T. cruzi.
Although it is clear that an 83-kDa protein related to the
clone 9 gene is expressed in amastigotes of T. cruzi, it is still not
clear whether epimastigotes and trypomastigotes express this
antigen. The lack of recognition by specific antibodies of an
83-kDa molecule can be explained by posttranslational modi-
fications. A 47-kDa band was recognized in epimastigotes by
antibodies specific for the His-25kDa protein. This protein had
been recognized previously using polyclonal antibodies specific
for a recombinant protein encoded by the asp-2 gene of the
Brazil strain of T. cruzi (20). We also detected a cross-reaction
with a 67-kDa polypeptide present in trypomastigotes. The
nature of the identity of these polypeptides with ASP-2 antigen
is unknown and remains to be investigated.
The fact that at the level of the predicted amino acid se-
quences, the clone 9 gene shared 82.7% identity with the asp-2
gene isolated from the T. cruzi Brazil strain is noteworthy.
Sequence conservation was observed in several of the previ-
ously described epitopes recognized by mouse and human
CD8 T cells primed during infection. For example, the se-
quences encoding two epitopes recognized by H-2Kb-restricted
CD8 T cells (DNRQYSFV and VNHRFTLV) were entirely
conserved (19). Conservation was also observed for epitope
FVNHRFTLV recognized by HLA-A2-restricted human
CD8 T cells. A second HLA-A2-restricted human CD8
T-cell epitope (WVFPESISPV) had a single amino acid sub-
stitution (which is underlined in the sequence) in the clone 9
gene product (WVFPEGISPV). Whether this single amino
acid substitution interferes with HLA-A2-restricted CTL rec-
ognition will be important to be determined. Also relevant is
TABLE 2. IFN- secretion by spleen cells from BALB/c mice immunized with different plasmids upon in vitro restimulation






No Ab Rat IgG Anti-CD4 MAb Anti-CD8 MAb Anti-CD4 andanti-CD8 MAbs
pcDNA3 0.2 0.27  0.01 0.2 0.2 0.2 0.2 0.2
pclone9 0.2 0.2 5.82  0.28c 5.28  1.55 0.84  0.29d 3.91  0.59e 1.12  0.59d
pSPclone9 0.2 NTf 4.16  1.34c 4.79  0.95 0.89  0.21d 3.24  0.50e 0.56  0.07d
pIgSPclone9 0.2 0.43  0.13 3.29  1.19c 3.45  0.54 0.65  0.07d 2.91  0.33e 0.52  0.07d
a BALB/c mice were immunized with the indicated plasmid as described in Materials and Methods. Two weeks after the last immunization, pooled spleen cells were
collected from three mice.
b Spleen cells were stimulated in vitro with 10 g of recombinant (Rec.) protein His-65kDa or recombinant TS per ml in the presence or absence of 10 g of rat
IgG per ml or with anti-CD4 or anti-CD8 MAb or anti-CD4 and anti-CD8 MAbs. The concentration of IFN- was estimated in cell culture supernatants, and results
are expressed as averages of triplicate cultures  SDs. This experiment was reproduced three times with identical results. No Ab, no antibody.
c Significantly different from values for the supernatants of cells cultured in the absence of the recombinant protein His-65kDa or in the presence of recombinant
TS (P  0.01 by the Student t test).
d Significantly different from values in the supernatants of cells cultured in the presence of rat IgG (P  0.01 by the Student t test).
e Not significantly different from values in the supernatants of cells cultured in the presence of rat IgG (P  0.05 by the Student t test).
f NT, not tested.
TABLE 3. NO secretion by spleen cells of DNA-immunized mice upon in vitro restimulation with the recombinant protein His-65kDa
Plasmida
Nitrite concn (M)b
Expt 1 Expt 2 Expt 3
Medium His-65kDa Medium His-65kDa Medium His-65kDa
pcDNA3 3.24  1.37 3.37  0.22c 2.73  1.27 3.11  0.58c 4.32  1.72 4.96  1.56c
pclone9 2.22  2.21 8.89  0.48d 1.65  0.88 14.54  1.12 6.86  3.72 27.11  1.16
pSPclone9 4.19  1.82 29.02  1.64 1.46  1.15 8.25  0.67 NTe NT
pIgSPclone9 4.44  5.56 27.74  1.05 1.84  1.15 5.27  0.11 2.54  1.77 20.83  2.66
a BALB/c mice were immunized with the indicated plasmid.
b Two to five weeks after the last immunization, spleen cells were collected and stimulated in vitro with the recombinant protein His-65kDa at a final concentration
of 1 g/ml or not stimulated (medium). Results represent the means obtained from triplicate cultures  SDs.
c Not significantly different from values in the supernatants of cells cultured with medium only (P  0.05 by the Student t test).
d Values in boldface type are significantly different from values in the supernatants of cells cultured with medium only (P  0.01 by the Student t test).
e NT, not tested.
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the fact that the sequence encoding the recently described
peptide representing a parasite ligand for host cells (VTVT
NVFLYNRPL) is entirely conserved in the clone 9 and asp-2
genes (21).
Using eukaryotic expression vectors harboring the clone 9
gene, we reported that specific immune responses to T. cruzi
could be generated after i.m. inoculation of plasmid. Three
different plasmids containing the clone 9 gene were used for
immunization. The difference between the three plasmids was
the presence of sequences encoding a secretory SP in plasmid
pSPclone9 or pIgSPclone9. We found that the vast majority of
the immunized BALB/c mice developed specific serum anti-
bodies as detected by ELISA.
Cell-mediated immune response was estimated in vitro by
the antigen-specific IFN- or IL-4 secretion. Upon in vitro
stimulation with the recombinant protein His-65kDa, spleen
cells from mice immunized with plasmid pclone9, pSPclone9,
or pIgSPclone9 secreted comparable levels of IFN-. We also
failed to observe significant differences among spleen cells of
mice injected with the different plasmids in experiments using
different concentrations of antigen in culture (0.1 to 10 g/ml
[data not shown]). We concluded that under the conditions
tested, the presence of different SPs does not interfere with the
priming or activation of IFN--producing cells in vivo.
An important characteristic of DNA immunization is the
ability to prime in vivo for specific CD8 T cells. Indeed,
earlier studies have shown that immunization with plasmids
containing T. cruzi genes primed CD8 T cells that were ca-
pable of lysing infected cells (19, 46) or inhibiting intracellular
parasite development in vitro (30). We attempted to detect the
presence of specific CD8 T cells using 14 different synthetic
peptides selected for the presence of putative sites for binding
to H-2Kd or H-2Ld. Using a very sensitive assay, the ELISPOT
assay, we could not detect the presence of peptide-specific
TABLE 4. Presence of anti-CD4 MAb inhibits NO secretion by spleen cells of pclone9-immunized mice upon in vitro restimulation









pcDNA3 2.10  0.49 2.58  1.05 4.28  0.67 3.06  0.40 2.46  0.08 3.06  0.70
pclone 9 2.42  0.45 15.44  0.24c 22.85  2.33 3.62  0.72d 18.03  2.50e 3.85  1.12d
a BALB/c mice were immunized with the indicated plasmids.
b Spleen cells were stimulated in vitro with 1 g of recombinant (Rec.) protein His-65kDa per ml in the presence or absence of 10 g of rat IgG per ml or with an
anti-CD4 or anti-CD8 MAb or anti-CD4 and anti-CD8 MAbs. The results are expressed as averages of triplicate cultures  SDs. No Ab, no antibody.
c Significantly different from values in the supernatants of cells cultured in the absence of the recombinant protein His-65kDa (P  0.01 by the Student t test).
d Significantly different from values in the supernatants of cells cultured in the presence of rat IgG (P  0.01 by the Student t test).
e Not significantly different from values in the supernatants of cells cultured in the presence of rat IgG (P  0.05 by the Student t test).
TABLE 5. ELISPOT assay for detection of peptide-specific IFN--secreting cells
Peptideb in culture
No. of IFN- secreting cells/106 spleen cells of mice immunized with plasmida:
pcDNA3 pclone9 pIgSPclone9 p154/13
No peptide 17.3  8.3 11.3  2.3 9.3  6.1 9.2  1.2
CYLQRPTAV 22.0  0.0 25.0  1.4 5.0  1.4 NTc
PYEIVAGYI 14.0  2.8 29.0  9.9 9.0  1.4 NT
GYVYVDGVI 21.3  3.1 24.0  5.3 28.7  9.2 NT
LYSDGALHL 22.0  2.0 22.7  3.1 27.3  5.8 NT
VYIVHEHNL 31.3  15.2 26.7  3.1 27.3  2.3 NT
DYRCVHASV 28.7  1.2 34.0  6.0 31.3  12.2 NT
TPTAGLVGF 16.7  3.1 26.0  5.3 22.7  8.3 NT
RPNMSRHLF 12.7  8.1 10.0  3.5 14.0  4.0 NT
YSDGALHLL 14.0  0.0 34.0  5.3 3.3  1.1 NT
ESKSGDAPL 18.0  0.0 17.0  1.4 14.0  0.0 NT
GSRNGNDRL 23.3  11.0 20.7  6.4 12.7  4.2 NT
ESEPKRPNM 22.7  4.2 16.7  2.3 18.0  6.0 NT
ESSTPTAGL 20.0  8.5 17.0  1.4 12.0  2.8 NT
VSWGEPKSL 16.0  2.8 22.0  2.8 11.0  4.2 NT
Controls
TS359–367 (IYNVGQVSI) 13.3  3.1 NT NT 153.3  9.5
Rec. protein His-65kDad 12.0  6.0 101.3  10.3 114.0  12.5 NT
Rec. protein TSd 6.0  3.5 22.0  8.5 3.0  1.4 121.3  5.8
a The number of IFN- secreting cells was determined by ELISPOT assay. BALB/c mice were immunized with the indicated plasmid as described in Materials and
Methods. Two weeks after the last immunization, pooled spleen cells were collected from three mice.
b The final concentration of each peptide in culture was 2 M.
c NT, not tested.
d The final concentration of each recombinant (Rec.) protein in culture was 10 g/ml (0.15 M).
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IFN--secreting cells in the spleens of mice immunized with
plasmid pclone9 or pIgSPclone9. This negative result could not
be attributed to the ELISPOT assay, because we could easily
and reproducibly detect the presence of IFN--secreting cells
specific for the CD8 T-cell epitope TS359-367 (IYNVGQVSI) in
the spleens of mice immunized with plasmid p154/13 (30).
Nevertheless, we cannot completely exclude the possibility that
the putative epitope(s) has sites for binding to H-2Kd, H-2Dd,
or H-2Ld distinct from the sites currently known for other
antigens.
The fact that immunization of BALB/c mice with eukaryotic
expression plasmids containing the clone 9 gene elicited spe-
cific immune responses allowed us to determine whether DNA
immunization with plasmid pclone9 or pSPclone9 could pro-
vide protective immunity against experimental infection. We
found that immunizing the mice with these plasmids signifi-
cantly reduced the peak parasite levels and that none of these
mice died. In the experiments performed, 100% of the mice
immunized with plasmid pclone9 or pSPclone9 survived a le-
thal challenge with bloodstream trypomastigotes. In contrast,
94.4% of the mice immunized with the control pcDNA3 plas-
mid died after challenge.
Our data on the protective immune response elicited by
DNA immunization with the clone 9 gene confirms and extends
the results of the recently published study by Garg and Tarle-
ton (10). Their study reported that immunization of C57BL/6
mice with a plasmid harboring the asp-2 gene elicited specific
antibodies and CD8 T cells (10). Immunization with the asp-2
gene provided protective immunity against a lethal challenge
with bloodstream forms of T. cruzi (Brazil strain), as estimated
by the reduction of acute parasitemia and mortality. Also im-
portant was the observation that protective immunity induced
by genetic vaccination with the asp-2 gene reduced the skeletal
muscle inflammation observed in the chronic phase of infec-
tion (10). Together, both studies emphasize the importance of
the immune response to ASP-2 for the development of pro-
tective immunity to T. cruzi infection.
Although the protective mechanisms mediated in vivo by
immunization with plasmids containing the clone 9 gene were
not addressed in the present study, it is plausible that IFN--
secreting T cells have a role in protection. Solid previous work
established that T cells and IFN- participate in the control of
parasitemia and mortality during the natural course of T. cruzi
infection in mice (13, 18, 32, 40, 42; reviewed in reference 43).
In addition to secreting IFN-, spleen cells from mice immu-
nized with plasmids containing the clone 9 gene also produced
NO, a potent inhibitor of T. cruzi development in vivo (22, 24,
31, 44). Our results are compatible with those of recent studies
showing that a strong Th1, but not Th2, immune response can
provide a high degree of systemic immunity against experimen-
tal T. cruzi infection in BALB/c mice (11, 12, 37). However, the
precise role of these IFN--secreting CD4 T cells in protec-
tive immunity remains to be determined. Until now, there has
been no clear evidence that specific CD4 Th1 cells alone can
provide protective immunity against T. cruzi infection (11, 12,
37). These cells most likely have to interact with other T- and
B-cell subsets in order to provide optimal protection against
systemic infection. Future studies will be required to elucidate
the effector immune mechanisms involved during the protec-
tive immune response induced by genetic vaccination with the
clone 9 gene.
It seems less likely that antibodies to the ASP-2 antigen
participate in protective immunity. Amastigotes are predomi-
nantly intracellular and have never been described as targets of
protective antibodies. On the other hand, extracellular trypo-
FIG. 7. Trypomastigote-induced parasitemia and mortality in
BALB/c mice immunized with plasmids pclone9 and pSPclone9.
BALB/c mice were immunized with pclone9, pSPclone9, or pcDNA3.
Ten days after the last immunization, mice were challenged intraperi-
toneally with bloodstream trypomastigotes. (A) Course of infection,
estimated by the number of trypomastigotes per milliliter of blood.
Results are the means  SDs obtained from mice immunized with
pclone9 (n  12), pSPclone9 (n  12), or pcDNA3 (n  10). At the
peak of infection (day 8), the numbers of parasites in mice immunized
with the different plasmids were compared by one-way ANOVA
and Tukey HSD tests. In mice immunized with plasmid pclone9 or
pSPclone9, we observed a significant reduction in the peak number of
parasites from the number in animals immunized with pcDNA3 plas-
mid (P  0.0001 by one-way ANOVA). There was no statistical dif-
ference between the numbers of parasites observed in mice immunized
with pclone9 versus pSPclone9 (P  0.05 by Tukey HSD test).
(B) Kaplan-Meier curves for survival of mice immunized with pclone9
(n 12), pSPclone9 (n 12), or pcDNA3 (n 10). The survival times
for mice immunized with pclone9 or pSPclone9 were significantly dif-
ferent from that of mice immunized with pcDNA3 (control) (P 
0.0001 by log-rank test).
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mastigotes, which are classically described as targets for pro-
tective antibodies, were not recognized by antibodies from
mice immunized with plasmids containing the clone 9 gene
(Fig. 6C and D).
In summary, our results confirm and extend the results of
earlier studies obtained by different research groups showing
that DNA immunization can be another way to induce protec-
tive immune responses against experimental T. cruzi infection.
The fact that DNA immunization with cDNA from amasti-
gotes is a feasible strategy to induce immunity against T. cruzi
may greatly facilitate future studies on immunity to these forms
of the parasite using individual genes or cDNA libraries. Stud-
ies on the immune response to amastigote antigens can provide
relevant basic knowledge on the complex immunopathology of
Chagas’ disease and may be of importance for vaccine devel-
opment.
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